

#26
8-29-03
[Signature]

Due Date: August 28, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Norbert O. Reich et al	Examiner:	Patrick T. Lewis
Serial No.:	09/485,071	Group Art Unit:	1623
Filed:	February 3, 2000	Docket:	G&C 30794.30-US-WO
Title:	MODULATORS OF DNA CYTOSINE-5 METHYLTRANSFERASE AND METHODS FOR USE THEREOF		

FAX RECEIVED
AUG 28 2003
GROUP 1600

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on August 28, 2003.

By: [Signature]

Name: Karen S. Canady

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL

Dear Sir:

This communication is submitted in response to the Office Action dated July 28, 2003.

REMARKS

At pages 2-3 of the Office Action, the Examiner required restriction of the application to one of 110 allegedly distinct inventions, corresponding to claims 31, 34 and 36-50, drawn to a synthetic oligonucleotide of at least 26 nucleotides in length comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and comprising a nucleotide sequence selected from the group consisting of TCACGTCA and SEQ ID NO: 1-4 and 6-110.

Applicants provisionally elect claims relating to GC box pMET, SEQ ID NO: 10 for examination, namely claims 31 and 46.

Applicants believe the restriction requirement to be issued in error, and accordingly, this election is made with traverse. The restriction requirement is in error for several reasons. First, the